Background This meta-analysis evaluated the real-world effectiveness of
onabotulinumtoxinA (BOTOX®), the first preventive treatment FDA-approved specifically for …

Purpose of review: Medication-overuse headache (MOH) is an important problem
worldwide, with different areas of controversy regarding its entity. This article reviews the risk …

Background The frequent use of medication to treat migraine attacks can lead to an increase
in migraine frequency and is called medication‐overuse headache (MOH). Methods Based …

Objective To evaluate the efficacy, tolerability, and safety of eptinezumab 100 and 300 mg
compared with placebo in patients with the dual diagnosis of chronic migraine (CM) and …

Background: German authorities reimburse migraine prevention with erenumab only in
patients who previously did not have therapeutic success with at least five oral prophylactics …

Abstract Background The PREEMPT Studies established onabotulinumtoxinA as preventive
treatment for adults with chronic migraine (CM). The purpose of the RE al-life use of …

Objective This post hoc analysis in patients medically diagnosed with chronic migraine (CM)
and medication‐overuse headache (MOH) evaluated reductions in the use of acute …

Introduction Numerous medications are used for the preventive treatment of chronic
migraine (CM), including oral treatments, onabotulinumtoxinA (onabotA; BOTOX), and …

OnabotulinumtoxinA (BT-A) is one of the few drugs approved for the preventive treatment of
chronic migraine (CM). Despite this, some aspects of its mechanism of action are still a …

Background: Despite numerous studies that have investigated clinical, radiological, and
biochemical response predictors, the clinical profile of those patients who might benefit from …